MX9205127A - Una composicion farmaceutica y un metodo para usar una combinacion de un agente uricosurico y un antagonista eaa. - Google Patents
Una composicion farmaceutica y un metodo para usar una combinacion de un agente uricosurico y un antagonista eaa.Info
- Publication number
- MX9205127A MX9205127A MX9205127A MX9205127A MX9205127A MX 9205127 A MX9205127 A MX 9205127A MX 9205127 A MX9205127 A MX 9205127A MX 9205127 A MX9205127 A MX 9205127A MX 9205127 A MX9205127 A MX 9205127A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- pharmaceutical composition
- uricosuric agent
- eaa antagonist
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención es un compuesto farmacéutico que tiene una combinación de un agente uricosúrico tal como la probenecida o similar y un antagonista excitador de aminoácidos útil para el tratamiento de un padecimiento ventajosamente afectado por el tratamiento con un antagonista excitador de aminoácidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75640191A | 1991-09-09 | 1991-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9205127A true MX9205127A (es) | 1993-07-01 |
Family
ID=25043303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9205127A MX9205127A (es) | 1991-09-09 | 1992-09-08 | Una composicion farmaceutica y un metodo para usar una combinacion de un agente uricosurico y un antagonista eaa. |
Country Status (16)
Country | Link |
---|---|
US (4) | US5407935A (es) |
EP (1) | EP0603301B1 (es) |
JP (1) | JP3218038B2 (es) |
AT (1) | ATE162075T1 (es) |
AU (1) | AU660717B2 (es) |
CA (1) | CA2115442C (es) |
DE (1) | DE69224069T2 (es) |
DK (1) | DK0603301T3 (es) |
ES (1) | ES2113957T3 (es) |
GR (1) | GR3026369T3 (es) |
MX (1) | MX9205127A (es) |
NO (1) | NO307645B1 (es) |
NZ (1) | NZ244243A (es) |
PT (1) | PT100850B (es) |
WO (1) | WO1993004688A1 (es) |
ZA (1) | ZA926837B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU660717B2 (en) * | 1991-09-09 | 1995-07-06 | Warner-Lambert Company | Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist |
US5318985A (en) * | 1991-12-20 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Potentiation of NMDA antagonists |
US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
JPH07505908A (ja) * | 1992-09-28 | 1995-06-29 | マックセチーニ、マリア ルイザ | Nmda受容体のアロステリックモジュレーター |
AU735389B2 (en) | 1996-07-22 | 2001-07-05 | Cognetix, Inc. | Use of conantokins |
US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
CA2261568A1 (en) | 1996-07-22 | 1998-01-29 | University Of Utah Research Foundation | Conantokins |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
NZ508414A (en) * | 1998-05-26 | 2003-12-19 | Carlen Peter Louis | Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
US6399574B1 (en) | 2000-03-22 | 2002-06-04 | University Of Utah Research Foundation | Use of conantokins |
US7799794B2 (en) | 2000-06-28 | 2010-09-21 | Merck Sharp & Dohme Corp. | Treatment for cardiovascular disease |
US7276514B2 (en) * | 2002-05-15 | 2007-10-02 | Charitable Leadership Foundation - Medical Technology Acceleration Program | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
US20080051428A1 (en) * | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
EP1735057B1 (en) * | 2004-03-22 | 2015-02-25 | Apkarian Technologies LLC | Method and compositions for treatment of chronic neuropathic pain |
US8461223B2 (en) * | 2005-04-07 | 2013-06-11 | Aspen Aerogels, Inc. | Microporous polycyclopentadiene-based aerogels |
ITFI20050083A1 (it) * | 2005-04-29 | 2006-10-30 | Univ Firenze | Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock |
US8841333B2 (en) | 2005-05-09 | 2014-09-23 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating nephrolithiasis |
WO2007140293A2 (en) | 2006-05-25 | 2007-12-06 | Aspen Aerogels, Inc. | Aerogel compositions with enhanced performance |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
JP5978216B2 (ja) | 2010-09-10 | 2016-08-24 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | テオフィリンとフェブキソスタットの併用療法のための方法 |
US10806711B2 (en) | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
AU2014244053B2 (en) | 2013-03-13 | 2018-08-30 | University Of Cincinnati | Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist |
US20170143681A1 (en) | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
EP3427729A1 (en) * | 2017-07-13 | 2019-01-16 | Paris Sciences et Lettres - Quartier Latin | Probenecid for use in treating epileptic diseases, disorders or conditions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812458A (en) * | 1986-09-16 | 1989-03-14 | A/S Ferrosan | 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics |
DK146787A (da) * | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
EP0501378B1 (en) * | 1991-02-28 | 1995-01-11 | Merrell Dow Pharmaceuticals Inc. | NMDA Antagonists |
AU660717B2 (en) * | 1991-09-09 | 1995-07-06 | Warner-Lambert Company | Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist |
-
1992
- 1992-09-02 AU AU25943/92A patent/AU660717B2/en not_active Ceased
- 1992-09-02 DE DE69224069T patent/DE69224069T2/de not_active Expired - Fee Related
- 1992-09-02 WO PCT/US1992/007540 patent/WO1993004688A1/en active IP Right Grant
- 1992-09-02 CA CA002115442A patent/CA2115442C/en not_active Expired - Fee Related
- 1992-09-02 ES ES92919882T patent/ES2113957T3/es not_active Expired - Lifetime
- 1992-09-02 AT AT92919882T patent/ATE162075T1/de not_active IP Right Cessation
- 1992-09-02 EP EP92919882A patent/EP0603301B1/en not_active Expired - Lifetime
- 1992-09-02 DK DK92919882T patent/DK0603301T3/da active
- 1992-09-02 JP JP50544593A patent/JP3218038B2/ja not_active Expired - Fee Related
- 1992-09-07 NZ NZ244243A patent/NZ244243A/en unknown
- 1992-09-08 MX MX9205127A patent/MX9205127A/es not_active IP Right Cessation
- 1992-09-08 PT PT100850A patent/PT100850B/pt not_active IP Right Cessation
- 1992-09-08 ZA ZA926837A patent/ZA926837B/xx unknown
-
1993
- 1993-04-19 US US08/049,228 patent/US5407935A/en not_active Expired - Fee Related
-
1994
- 1994-03-08 NO NO940809A patent/NO307645B1/no not_active IP Right Cessation
-
1995
- 1995-10-05 US US08/539,398 patent/US5627168A/en not_active Expired - Fee Related
-
1996
- 1996-12-31 US US08/775,637 patent/US5767119A/en not_active Expired - Fee Related
-
1998
- 1998-03-13 GR GR980400554T patent/GR3026369T3/el unknown
- 1998-03-27 US US09/049,495 patent/US5942513A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1993004688A1 (en) | 1993-03-18 |
EP0603301A1 (en) | 1994-06-29 |
JP3218038B2 (ja) | 2001-10-15 |
US5407935A (en) | 1995-04-18 |
EP0603301B1 (en) | 1998-01-14 |
PT100850A (pt) | 1993-10-29 |
US5942513A (en) | 1999-08-24 |
DK0603301T3 (da) | 1998-09-14 |
NO307645B1 (no) | 2000-05-08 |
NZ244243A (en) | 1995-07-26 |
AU660717B2 (en) | 1995-07-06 |
JPH06510544A (ja) | 1994-11-24 |
US5627168A (en) | 1997-05-06 |
AU2594392A (en) | 1993-04-05 |
ATE162075T1 (de) | 1998-01-15 |
CA2115442C (en) | 2003-09-23 |
ES2113957T3 (es) | 1998-05-16 |
PT100850B (pt) | 1999-07-30 |
US5767119A (en) | 1998-06-16 |
DE69224069D1 (de) | 1998-02-19 |
GR3026369T3 (en) | 1998-06-30 |
NO940809L (no) | 1994-03-08 |
ZA926837B (en) | 1994-03-08 |
DE69224069T2 (de) | 1998-07-02 |
CA2115442A1 (en) | 1993-03-18 |
NO940809D0 (no) | 1994-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9205127A (es) | Una composicion farmaceutica y un metodo para usar una combinacion de un agente uricosurico y un antagonista eaa. | |
EA200100572A1 (ru) | Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
CY1107615T1 (el) | Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων | |
ATE173630T1 (de) | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
PT705100E (pt) | Guanidinas substituidas terapeuticas | |
ES2059121T5 (es) | Uso de agentes sensibilizantes de la insulina para tratar la hipertension. | |
EA200301253A1 (ru) | Применение остеопонтина для лечения и/или профилактики неврологических заболеваний | |
PL310475A1 (en) | Application of anticonvulsants in treating neuro-aids diseases | |
ES2058815T3 (es) | Composiciones farmaceuticas para el tratamiento de desarreglos gastrointestinales. | |
DE69413789D1 (de) | 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
NO993627L (no) | Anvendelse av en forbindelse for fremstilling av et legemiddel | |
FR2786100B1 (fr) | Nouvelle application therapeutique de la nicergoline | |
EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии | |
TR199801801T2 (xx) | Madde k�t�ye kullan�m�n�n tedavisi. | |
DE69800906D1 (de) | Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie | |
NO984198D0 (no) | Fremgangsmåte for behandling av aggresjon | |
CY1107048T1 (el) | Χρηση ριλουζολης ΄η των αλατων της για τη προληψη και τη θepαπεια της αδρενολευκοδυστροφιας | |
EA199800820A1 (ru) | Способ лечения злоупотребления лекарственными средствами | |
UY26735A1 (es) | Métodos y composiciones para tratar flavivirus y pestivirus | |
EA199800575A1 (ru) | Производные пиперазина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |